RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Jan. 4, 2006--Adherex Technologies Inc. (TSX:AHX)(AMEX:ADH), a biopharmaceutical company with a broad portfolio of oncology products under development, today announced the activation of a Phase I clinical trial of the combination of eniluracil and 5-fluorouracil (5-FU). This study follows Adherex’s announcement in late November 2005 that the U.S. Food and Drug Administration (FDA) had cleared its Investigational New Drug (IND) application for eniluracil.
